Ocugen, Inc. (OCGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OCGN SEC filings page.
Ocugen, Inc. (OCGN) reported $4.4M in revenue for fiscal year 2025, up 8.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Ocugen remains a development-stage business: modest revenue sits beside heavy research spending, recurring cash use, and negative equity.
The near match between operating cash flow of-$57.0M and free cash flow of-$57.1M in FY2025 shows cash consumption is mainly operational rather than capital-intensive. With R&D at 9.0x revenue, the company’s financial profile is shaped by ongoing development spending, not an established sales engine.
Revenue remained below
By FY2025, liabilities exceeded assets, leaving negative equity and a current ratio of 1.1x. Reported liquidity equaled 3.9 months of annual operating outflow, while financing covered only part of operating cash needs, making external funding central to the balance-sheet structure.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ocugen, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ocugen, Inc. held $18.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $57.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ocugen, Inc. scores 15/100 among other emerging companies.
Ocugen, Inc. had 328M shares outstanding at the end of fiscal year 2025, against 292M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Ocugen, Inc. scores 44/100 among other emerging companies.
Ocugen, Inc. spent $39.8M on research and development in fiscal year 2025, which was 59.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Ocugen, Inc. scores 82/100 among other emerging companies.
Ocugen, Inc. reported revenue of $4.4M in fiscal year 2025, against $4.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Ocugen, Inc. scores 25/100 among other emerging companies.
Ocugen, Inc.'s operations used $57.0M of cash in fiscal year 2025, against $42.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Ocugen, Inc. scores 49/100 among other emerging companies.
Ocugen, Inc.'s cash, cash equivalents and investments came to $18.6M at the end of fiscal year 2025, against $55.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ocugen, Inc. scores 35/100 among other emerging companies.
Ocugen, Inc. scores -14.04, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($345.9M) relative to total liabilities ($55.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ocugen, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Ocugen, Inc. reported a net loss of $68.0M while operations used $57.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Ocugen, Inc. reported an operating loss of $62.9M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Ocugen, Inc. generated $1.5M in revenue in Q2 2026. This represents an increase of 8.4% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.
Ocugen, Inc.'s EBITDA was -$15.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.1% from the same quarter a year earlier. Against the prior quarter it is up 8.1%.
Ocugen, Inc. reported -$24.9M in net income in Q2 2026. This represents a decrease of 68.8% from the same quarter a year earlier. Against the prior quarter it is down 29.7%.
Ocugen, Inc. earned -$0.07 per diluted share (EPS) in Q2 2026. This represents a decrease of 40.0% from the same quarter a year earlier. Against the prior quarter it is down 16.7%.
Cash & Balance Sheet
Ocugen, Inc. recorded an outflow of $12.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 13.4% from the same quarter a year earlier. Against the prior quarter it is up 43.9%.
Ocugen, Inc. held $100.1M in cash against $1.7M in long-term debt as of Q2 2026, with $133.1M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
Ocugen, Inc. invested $10.7M in research and development in Q2 2026. This represents an increase of 27.2% from the same quarter a year earlier. Against the prior quarter it is down 5.0%.
Ocugen, Inc. invested $21K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 51.2% from the same quarter a year earlier. Against the prior quarter it is up 250.0%.
Not reported for Q2 2026.
OCGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M+8.4% | $1.5M+3.5% | N/A | $1.8M+54.2% | $1.4M+20.3% | $1.5M+46.1% | $764K-45.8% | $1.1M-69.3% |
| R&D Expenses | $10.7M+27.2% | $11.3M+18.1% | N/A | $11.1M+37.5% | $8.4M-5.6% | $9.5M+39.6% | $8.3M+6.6% | $8.1M+15.0% |
| SG&A Expenses | $7.2M+7.0% | $8.1M+25.8% | N/A | $8.2M+31.0% | $6.8M-12.0% | $6.5M+0.8% | $6.3M+22.5% | $6.3M-30.9% |
| Operating Income | -$16.4M-19.2% | -$17.8M-23.0% | N/A | -$17.6M-33.0% | -$13.8M+10.7% | -$14.5M-18.7% | -$13.8M-20.1% | -$13.3M-6.6% |
| EBITDA | -$15.8M-20.1% | -$17.2M-24.0% | N/A | N/A | -$13.2M | -$13.9M | N/A | N/A |
| Interest Expense | $4.5M+273.0% | $1.3M+8.3% | N/A | $1.3M+4382.8% | $1.2M | $1.2M | N/A | $29K |
| Net Income | -$24.9M-68.8% | -$19.2M-24.9% | N/A | -$20.1M-54.6% | -$14.7M+3.5% | -$15.3M-28.7% | -$13.8M-26.9% | -$13.0M-10.7% |
| EPS (Basic) | -$0.07-40.0% | -$0.06-20.0% | N/A | N/A | -$0.05-25.0% | -$0.050.0% | N/A | N/A |
| EPS (Diluted) | -$0.07-40.0% | -$0.06-20.0% | N/A | N/A | -$0.05-25.0% | -$0.050.0% | N/A | N/A |
| Diluted Shares (Avg) | 339M+16.0% | 328M+12.2% | N/A | N/A | 292M+13.5% | 292M+13.5% | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
OCGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $124.2M+131.8% | $56.9M-11.7% | $43.5M-47.2% | $57.6M-7.0% | $53.6M+32.2% | $64.5M+24.5% | $82.4M+27.7% | $61.9M-17.1% |
| Current Assets | $106.7M+224.5% | $38.6M-12.3% | $24.3M-60.5% | $37.6M-7.5% | $32.9M+76.6% | $44.0M+46.6% | $61.7M+43.5% | $40.7M-28.1% |
| Cash & Equivalents | $100.1M+270.4% | $31.9M-15.6% | $18.6M-68.4% | $32.9M-15.7% | $27.0M+72.1% | $37.8M+43.3% | $58.8M+49.1% | $39.0M-27.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $140.8M+178.5% | $51.1M+5.3% | $55.7M+5.4% | $54.1M+153.7% | $50.5M+114.0% | $48.5M+125.4% | $52.8M+120.2% | $21.3M-14.4% |
| Current Liabilities | $133.1M+639.8% | $20.7M+22.6% | $23.0M+6.7% | $20.4M+29.2% | $18.0M+0.1% | $16.9M+5.2% | $21.6M+26.3% | $15.8M-20.1% |
| Non-Current Liabilities | $7.7M-76.4% | $30.4M-4.0% | $32.6M+4.5% | $33.7M+507.9% | $32.6M+476.9% | $31.7M+477.4% | $31.2M+352.9% | $5.5M+7.5% |
| Long-Term Debt | $1.7M-93.8% | $24.2M-12.6% | $27.5M+0.7% | $28.4M+1707.8% | $28.0M+1705.7% | $27.7M+1704.9% | $27.3M+876.6% | $1.6M+5.1% |
| Total Equity | -$16.6M-642.5% | $5.8M-63.5% | -$12.2M-141.1% | $3.5M-91.3% | $3.1M-82.0% | $15.9M-47.4% | $29.6M-27.0% | $40.6M-18.4% |
| Retained Earnings | -$452.1M-22.1% | -$427.2M-20.2% | -$408.1M-19.9% | -$390.4M-19.6% | -$370.3M-18.2% | -$355.6M-19.3% | -$340.2M-18.9% | -$326.3M-18.6% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
OCGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.2M-13.7% | -$21.8M-12.6% | N/A | -$12.9M-14.6% | -$10.7M-8.3% | -$19.4M-82.7% | -$10.4M+8.3% | -$11.3M+17.8% |
| Depreciation & Amortization | $600K0.0% | $600K0.0% | N/A | N/A | $600K | $600K | N/A | N/A |
| Stock-Based Compensation | $1.8M-0.7% | $3.4M+80.3% | N/A | $2.0M+4.4% | $1.8M-2.8% | $1.9M+7.0% | N/A | $1.9M-13.0% |
| Capital Expenditures | $21K-51.2% | $6K-62.5% | N/A | $91K-82.1% | $43K-91.6% | $16K-99.3% | $13K-99.5% | $507K-84.9% |
| Free Cash Flow | -$12.2M-13.4% | -$21.8M-12.5% | N/A | -$13.0M-10.4% | -$10.8M-3.3% | -$19.4M-49.6% | -$10.4M+26.0% | -$11.8M+31.0% |
| Investing Cash Flow | -$21K+76.1% | -$6K+94.1% | N/A | -$86K+83.0% | -$88K+82.8% | -$102K+95.7% | -$13K+99.5% | -$507K+84.9% |
| Financing Cash Flow | $80.4M+131650.8% | $35.0M+2910.0% | N/A | $18.5M-46.8% | $61K+35.6% | -$1.2M-758.6% | $30.2M+188475.0% | $34.8M+99488.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
OCGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1105.1% | -1163.7% | N/A | -1006.0% | -1004.7% | -979.1% | -1811.5% | -1166.5% |
| Net Margin | -1671.8% | -1250.9% | N/A | -1144.5% | -1073.5% | -1036.5% | -1809.7% | -1141.7% |
| Return on Equity | N/A | -330.4%-233.9pp | N/A | -567.5%-535.6pp | -482.9%-392.7pp | -96.5%-57.1pp | -46.7%-19.8pp | -31.9%-8.4pp |
| Return on Assets | -20.0%+7.5pp | -33.7%-9.9pp | N/A | -34.8%-13.9pp | -27.5%+10.2pp | -23.8%-0.8pp | -16.8%+0.1pp | -20.9%-5.2pp |
| Current Ratio | 0.80-1.0x | 1.86-0.7x | 1.06-1.8x | 1.85-0.7x | 1.83+0.8x | 2.60+0.7x | 2.86+0.3x | 2.58-0.3x |
| Debt-to-Equity | N/A | 4.17+2.4x | N/A | 8.04+8.0x | 9.18+9.1x | 1.74+1.7x | 0.92+0.9x | 0.040.0x |
| Asset Turnover | 0.010.0x | 0.030.0x | N/A | 0.030.0x | 0.030.0x | 0.020.0x | 0.010.0x | 0.020.0x |
| FCF Margin | -821.2% | -1422.0% | N/A | -742.4% | -784.6% | -1308.1% | -1358.3% | -1036.9% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$12.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ocugen, Inc. OCGN | FY2025 | $4.4M | -$68.0M | N/A | $345.9M | 42/100 |
| 4D Molecular Therapeutics, Inc. FDMT | FY2025 | $85.2M | -$140.1M | N/A | $755.2M | 71/100 |
| MBX Biosciences, Inc. MBX | FY2025 | N/A | -$87.0M | N/A | $2.7B | — |
| Benitec Biopharma Inc. BNTC | FY2026 | N/A | -$45.5M | N/A | $313.2M | — |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $307.5M | — |
| Design Therapeutics, Inc. DSGN | FY2025 | $0 | -$69.8M | N/A | $772.3M | — |
Where Ocugen, Inc. Ranks
Frequently Asked Questions
What is Ocugen, Inc.'s annual revenue?
Ocugen, Inc. (OCGN) reported $4.4M in total revenue for fiscal year 2025. This represents a 8.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ocugen, Inc.'s revenue growing?
Ocugen, Inc. (OCGN) revenue grew by 8.8% year-over-year, from $4.1M to $4.4M in fiscal year 2025.
Is Ocugen, Inc. profitable?
No, Ocugen, Inc. (OCGN) reported a net income of -$68.0M in fiscal year 2025.
What is Ocugen, Inc.'s EBITDA?
Ocugen, Inc. (OCGN) had EBITDA of -$60.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ocugen, Inc. have?
As of fiscal year 2025, Ocugen, Inc. (OCGN) had $18.6M in cash and equivalents against $27.5M in long-term debt.
What is Ocugen, Inc.'s free cash flow?
Ocugen, Inc. (OCGN) recorded an outflow of $57.1M in free cash flow during fiscal year 2025. This represents a -25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ocugen, Inc.'s operating cash flow?
Ocugen, Inc. (OCGN) recorded an outflow of $57.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Ocugen, Inc.'s total assets?
Ocugen, Inc. (OCGN) had $43.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ocugen, Inc.'s capital expenditures?
Ocugen, Inc. (OCGN) invested $185K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ocugen, Inc. spend on research and development?
Ocugen, Inc. (OCGN) invested $39.8M in research and development during fiscal year 2025.
What is Ocugen, Inc.'s current ratio?
Ocugen, Inc. (OCGN) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.
What is Ocugen, Inc.'s return on assets (ROA)?
Ocugen, Inc. (OCGN) had a return on assets of -156.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ocugen, Inc.'s P/E ratio?
Ocugen, Inc. (OCGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $345.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ocugen, Inc.'s price-to-sales ratio?
Ocugen, Inc. (OCGN) trades at 78.4x sales, its market capitalization divided by revenue of $4.4M revenue, FY2025. The market capitalization is $345.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Ocugen, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Ocugen, Inc. (OCGN) held $18.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $57.0M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Ocugen, Inc.'s debt-to-equity ratio negative or not reported?
Ocugen, Inc. (OCGN) has negative shareholder equity of -$12.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Ocugen, Inc.'s Altman Z-Score?
Ocugen, Inc. (OCGN) has an Altman Z-Score of -14.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ocugen, Inc.'s Piotroski F-Score?
Ocugen, Inc. (OCGN) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ocugen, Inc.'s earnings high quality?
Ocugen, Inc. (OCGN) reported a net loss of $68.0M while operations used $57.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ocugen, Inc. cover its interest payments?
Ocugen, Inc. (OCGN) reported an operating loss of $62.9M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ocugen, Inc.?
Ocugen, Inc. (OCGN) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.